BR112015023209A8 - novos medicamentos compreendendo uma composição de anticorpo enriquecida com uma carga principal de isoforma - Google Patents

novos medicamentos compreendendo uma composição de anticorpo enriquecida com uma carga principal de isoforma

Info

Publication number
BR112015023209A8
BR112015023209A8 BR112015023209A BR112015023209A BR112015023209A8 BR 112015023209 A8 BR112015023209 A8 BR 112015023209A8 BR 112015023209 A BR112015023209 A BR 112015023209A BR 112015023209 A BR112015023209 A BR 112015023209A BR 112015023209 A8 BR112015023209 A8 BR 112015023209A8
Authority
BR
Brazil
Prior art keywords
antibody composition
loading
antibody
enriched
major isoform
Prior art date
Application number
BR112015023209A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112015023209A2 (pt
Inventor
Chevreux Guillaume
Bihoreau Nicolas
Original Assignee
Lab Francais Du Fractionnement
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lab Francais Du Fractionnement filed Critical Lab Francais Du Fractionnement
Publication of BR112015023209A2 publication Critical patent/BR112015023209A2/pt
Publication of BR112015023209A8 publication Critical patent/BR112015023209A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Analytical Chemistry (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BR112015023209A 2013-03-15 2014-03-14 novos medicamentos compreendendo uma composição de anticorpo enriquecida com uma carga principal de isoforma BR112015023209A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1352360A FR3003171B1 (fr) 2013-03-15 2013-03-15 Nouveaux medicaments comprenant une composition d'anticorps enrichie en isoforme de charge majoritaire
PCT/EP2014/055179 WO2014140322A1 (fr) 2013-03-15 2014-03-14 Nouveaux médicaments comprenant une composition d'anticorps enrichie en isoforme de charge majoritaire

Publications (2)

Publication Number Publication Date
BR112015023209A2 BR112015023209A2 (pt) 2017-07-18
BR112015023209A8 true BR112015023209A8 (pt) 2018-01-23

Family

ID=48771615

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015023209A BR112015023209A8 (pt) 2013-03-15 2014-03-14 novos medicamentos compreendendo uma composição de anticorpo enriquecida com uma carga principal de isoforma

Country Status (11)

Country Link
US (1) US20160046722A1 (https=)
EP (1) EP2968533A1 (https=)
JP (1) JP2016512216A (https=)
KR (1) KR20150132522A (https=)
CN (1) CN105163758B (https=)
AU (1) AU2014230134A1 (https=)
BR (1) BR112015023209A8 (https=)
CA (1) CA2907358A1 (https=)
FR (1) FR3003171B1 (https=)
MX (1) MX2015012812A (https=)
WO (1) WO2014140322A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6454547B2 (ja) 2011-07-06 2019-01-16 ゲンマブ エー／エス 抗体重鎖のｃ末端の修飾による補体依存性細胞傷害の調節
DK3451820T3 (da) 2016-05-04 2021-01-18 Delaval Holding Ab Kassette og konnektor til en pattekop samt pattekop, der omfatter kassetten og konnektoren
FR3053688B1 (fr) * 2016-07-06 2026-05-01 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Mutants fc a activite fonctionnelle amelioree
EP3498293A1 (en) 2017-12-15 2019-06-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Treatment of monogenic diseases with an anti-cd45rc antibody
EP3626265A1 (en) 2018-09-21 2020-03-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-human cd45rc antibodies and uses thereof
SG11202107941TA (en) 2019-01-23 2021-08-30 Encefa Cd31 competitors and uses thereof
US20200369720A1 (en) * 2019-05-23 2020-11-26 Regeneron Pharmaceuticals, Inc. Characterization of domain-specific charge variants of antibodies
WO2021057726A1 (zh) * 2019-09-23 2021-04-01 南开大学 利用哺乳动物展示筛选FcγR特异性结合Fc
PL4401842T3 (pl) 2021-09-16 2025-11-24 Aboleris Pharma Domeny wiążące przeciwko ludzkiemu CD45RC i ich zastosowania
CN114236010A (zh) * 2021-12-18 2022-03-25 苏州莱奥生物技术有限公司 一种生物活性药物的药代动力学分析方法
CN115073548A (zh) * 2022-08-01 2022-09-20 上海蓝析生物技术有限公司 一种用于重组蛋白药物电荷异构体制备的缓冲体系

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL209392B1 (pl) * 1999-01-15 2011-08-31 Genentech Inc Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
FR2807767B1 (fr) * 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
FR2844513B1 (fr) * 2002-09-13 2007-08-03 Lab Francais Du Fractionnement Anticorps pour adcc et induisant la production de cytokines.
EP1553975B8 (en) * 2002-09-27 2023-04-12 Xencor, Inc. Optimized fc variants and methods for their generation
BRPI0315295C1 (pt) * 2002-10-17 2021-05-25 Genmab As anticorpo monoclonal humano isolado, célula hospedeira procariótica, composição farmacêutica, molécula biespecífica, usos de um anticorpo, métodos in vitro de detectar a presença de antígeno de cd20 ou uma célula que expressa cd20 em uma amostra, kit, e, vetor de expressão
CA2512729C (en) * 2003-01-09 2014-09-16 Macrogenics, Inc. Identification and engineering of antibodies with variant fc regions and methods of using same
FR2861078B1 (fr) * 2003-10-16 2007-09-21 Lab Francais Du Fractionnement NOUVELLES IgG3 UTILES POUR STIMULER LA PHAGOCYTOSE
JP5225069B2 (ja) * 2005-03-23 2013-07-03 ゲンマブ エー／エス 多発性骨髄腫の治療のためのｃｄ３８に対する抗体
JP6454547B2 (ja) * 2011-07-06 2019-01-16 ゲンマブ エー／エス 抗体重鎖のｃ末端の修飾による補体依存性細胞傷害の調節

Also Published As

Publication number Publication date
BR112015023209A2 (pt) 2017-07-18
JP2016512216A (ja) 2016-04-25
US20160046722A1 (en) 2016-02-18
EP2968533A1 (fr) 2016-01-20
FR3003171B1 (fr) 2015-04-10
CN105163758A (zh) 2015-12-16
AU2014230134A1 (en) 2015-10-29
CA2907358A1 (fr) 2014-09-18
FR3003171A1 (fr) 2014-09-19
MX2015012812A (es) 2016-05-09
CN105163758B (zh) 2017-11-17
KR20150132522A (ko) 2015-11-25
WO2014140322A1 (fr) 2014-09-18

Similar Documents

Publication Publication Date Title
BR112015023209A8 (pt) novos medicamentos compreendendo uma composição de anticorpo enriquecida com uma carga principal de isoforma
BR112015023520A2 (pt) purificação do conjugado de anticorpo-fármaco (adc)
EA201501032A1 (ru) Фармацевтическая композиция, способы лечения и ее применения
BR112015027319A8 (pt) Métodos e composições para modular a expressão de apolipoproteína (a)
BR112014026740A2 (pt) anticorpo, composição, métodos para tratar um mamífero e para fornecer um anticorpo com adcc realçada, e, uso de um anticorpo
BR112015011403A2 (pt) uso de akkermansia para o tratamento de distúrbios metabólicos
CL2017001364A1 (es) Nuevos indazoles sustituidos, procedimientos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos.
BR112015027288A8 (pt) uso de uma dose de imunossupressor, composição de nanocarreadores sintéticos tolerogênicos e kit
BR112015019657A2 (pt) composições tópicas e métodos de uso das mesmas
BR112015020050A2 (pt) material óptico, composto para material óptico e sua utilização
BR112017016636A2 (pt) formulação líquida estável para anticorpos monoclonais
BR112016001036A2 (pt) fusocinas envolvendo citocinas com afinidades de ligação de receptores fortemente reduzida
CL2021001395A1 (es) Compuestos derivados de panteteínas cíclicas; composición farmacéutica que los comprende; y su uso para aumentar las concentraciones de acetil-coa, para el tratamiento de cáncer, enfermedad inflamatoria, enfermedad neurodegenerativa, esclerosis múltiple, entre otras enfermedades.
BR112016001114A2 (pt) membros da família tnf direcionados modificados
EA201490420A1 (ru) ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С α-СУБЪЕДИНИЦАМИ ПОТЕНЦИАЛЗАВИСИМЫХ НАТРИЕВЫХ КАНАЛОВ (SCNxA), С ПОМОЩЬЮ МАЛЫХ МОЛЕКУЛ
BR112014017716A8 (pt) composições de ésteres de forbol, métodos para prevenir ou tratar acidente vascular cerebral e uso de ésteres de forbol
BR112014029442A2 (pt) composições antimucosas à base de xilitol e métodos e composições relacionados
BR112012023660A2 (pt) novos métodos para direcionar células-tronco cancerosas
BR112015004875A2 (pt) formulações de anticorpo e seus usos
BR112015029987A8 (pt) Beta-caseína a2 e a prevenção de inflamação do intestino
BR112016001446A2 (pt) Composições terapêuticas, produto de combinação, uso in vitro de flecainida e flecainida
BR112015030385A8 (pt) composto, composto para uso e composição farmacêutica
BR112015026388A8 (pt) uso de um composto de epoxi-tigliane, composto e composição farmacêutica
BR112013005706A2 (pt) métodos para preparar um extrato refinado e um extrato purificado de centella asiatica
BR112017010453A2 (pt) composição adesiva com mudança de cor

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements